Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.5714.

IVA has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. HC Wainwright raised their price objective on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Finally, Piper Sandler started coverage on shares of Inventiva in a research report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price objective for the company.

Inventiva Trading Up 4.7%

Shares of NASDAQ IVA opened at $4.00 on Monday. The stock has a 50 day moving average price of $5.17 and a 200 day moving average price of $4.18. Inventiva has a 52-week low of $2.11 and a 52-week high of $7.98.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.